Sophrosyne Capital’s Sonoma Pharmaceuticals SNOA Stock Holding History

Sophrosyne Capital’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-154	Closed	-$522K	–	78
2014 Q1	$522K	Buy	+154	New	+$523K	0.46%	40

Other funds holding SNOA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCM

Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Sophrosyne Capital's SNOA Position: Q2 2014 in Review

Sophrosyne Capital sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2014, closing a stake of 154 shares — an estimated $522K sold.

Sophrosyne Capital first reported a position in SNOA in Q1 2014 and held it in 1 quarter. The position peaked at $522K in Q1 2014. 18 funds tracked by Wall St. Rank hold SNOA as of Q2 2014.

Sophrosyne Capital reported no remaining Sonoma Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Sophrosyne Capital sold 154 Sonoma Pharmaceuticals shares in Q2 2014, an estimated $522K.
Sophrosyne Capital first reported a position in Sonoma Pharmaceuticals in Q1 2014 and held it in 1 quarter.
Sophrosyne Capital's Sonoma Pharmaceuticals position peaked at $522K in Q1 2014.
18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2014.

Based on Sophrosyne Capital's 13F filing for Q2 2014, filed 14 Aug 2014.